anteristech.com

What It Is

Anteris Technologies is a medical technology company focused on heart valve replacement. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a prosthetic valve for transcatheter aortic valve replacement. According to its website, the company’s principal executive office is located in Eagan, Minnesota, USA, with operations across the United States, Geneva, Brisbane, and Perth.

Core Features

The company’s technical focus is “biomimetic TAVR.” DurAVR® THV uses a single-piece design that closely resembles the shape of a native aortic valve, aiming to replicate the blood-flow performance of a healthy valve rather than simply enabling mechanical opening and closing. The website repeatedly highlights ADAPT® anti-calcification tissue technology, a material that has been used in cardiac and vascular patches and is claimed to have demonstrated long-term anti-calcification performance in prior clinical use. The site also presents clinical materials covering patients with small aortic annuli, 30-day and 1-year follow-up data, hemodynamic metrics, PPM (prosthesis-patient mismatch), and related topics.

Pricing

The official website does not provide any product pricing or a patient-facing purchase channel. High-risk implantable medical devices of this kind are typically used through regulatory approval, hospital procurement, physician assessment of indications, and insurance or public reimbursement systems. They should not be understood like ordinary consumer products or SaaS services.

Pros and Cons

The main advantage is its very clear technical positioning: it proposes a differentiated approach to key clinical pain points in TAVR, including hemodynamics, patients with small annuli, valve durability, and calcification. Its information disclosure is also relatively comprehensive, including news, white papers, conference presentations, and investor materials. The downside is that the website is highly technical, making it difficult for general patients to judge whether the product is suitable for them. In addition, many of the results come from company-disclosed conference materials or research updates, and still require validation through larger-scale, head-to-head studies, long-term follow-up, and regulatory review.

Who It’s For

This website is best suited for interventional cardiologists, structural heart disease centers, medical device researchers, hospital administrators, and healthcare investors. Patients may use it as a source for learning about emerging technology directions, but specific treatment decisions must still be made in consultation with a professional cardiac care team.

Access from China

Based on the nature of the website, it does not appear to be a blocked service and can usually be accessed directly. However, the official website does not appear to offer a Chinese-language interface, nor does it disclose China registration approval or local commercialization information. For Chinese users, it is mainly useful as a source of English-language reference materials.